期刊文献+

多药联合应用抗多重耐药鲍曼不动杆菌作用探讨 被引量:2

The Efficiency of Antibiotics combination in multi-drug resistant Acinetobacter baumarnii
下载PDF
导出
摘要 目的:分析不同抗菌药物单用和联合应用抗多重耐药鲍曼不动杆菌作用效果。方法:测定不同单种抗菌药物和多种抗菌药物联合应用,对鲍曼不动杆菌的最小抑菌浓度(MICs),然后用该浓度的不同单种抗菌药物及抗菌药物组合治疗鲍曼不动杆菌感染的小鼠,观察各药对感染小鼠的保护作用。结果:亚胺培南/西司他丁钠、哌拉西林/他唑巴坦、头孢哌酮/他唑巴坦、利福平、头孢他啶、丁胺卡那、环丙沙星的MIC分别为(μg/ml):64、512、64、250、2048、2048、150;特治星(128μg/ml)使丁胺卡那(μg/ml)从2048下降到64,舒普深(32μg/ml)可使利福平(μg/ml)从128下降到8,舒普深(32μg/ml)与丁胺卡那(1024μg/ml)联合有效,泰能(32μg/ml)与丁胺卡那(1024μg/ml)联合无效,特治星(256μg/ml)与利福平(128μg/ml)、泰能(16μg/ml)与利福平(128μg/ml)联合均无效;特治星(140.4mg/24h)、特治星(70.2mg/24h)与丁胺卡那(7.8mg/24h)、舒普深(41.6mg/24h)与丁胺卡那(7.8mg/24h)联合治疗,对感染小鼠的保护率(%)分别为30,100,100,舒普深(83.2mg/24h)、泰能(83.2mg/24h)治疗组小鼠全部死亡。结论:多重耐药鲍曼不动杆菌对常见抗菌药物的MIC均显著增加,特治星治疗多重耐药鲍曼不动杆菌比其他抗菌药物效好。特治星与丁胺卡那联合、舒普深与丁胺卡那联合联合治疗有效,而泰能对丁胺卡那、特治星等抗菌药物具有拮抗作用。合理的多药联合不仅对治疗多重耐药鲍曼不动杆菌有效,而且可以减少药物剂量。 Objective:To analyze the antibiosis effection of single antibiotics and antibiotics combination on multi-drug resistant Acinetobacter baumarnii in vivo and in vitro. Methods :We determined the minimum inhabitant concentration (MICs) of 7 antibiotics and several antibiotics combination to multi-drug resistant Acinetobacter baumarnii . The mice infected by multi-drug resistant Acinetobacter baumarnii were treated with Imipenem-Cilastatin Sodium, Cefperazone-Sulbactam , Piperacillin-Tazobactam, Amikacin and Suloerazon, Amikacin and Tazocillin. Results : The MIC (μg/ml) of Tienem, Tazocillin, Suloerazon, Rifampicin, Ceftazidime, Amikacin, Ciprofloxacin were 64,512,64,250, 2048,2048, 150, respectively. Tazocillin ( 128μg/ml ) could decreased the MIC of Amikacin from 2048 to 128, Suloerazon (32μg/ml) could decreased the MIC of Rifampicin from 250 to 16. The antibiotics combination of Suloerazon(32) and Amikacin(1024) could inhabit multi-drug resistant Acinetobacter baumarnii,but antibiotics combination of Tienem(32) and Amikacin(1024) ,Tazocillin(256) and Rifampicin(128) ,could not inhabit multi-drug resistant Acinetobacter baumarnii. The protection rate (%) of Tazocillin (140. 4 mg/24h), antibiotics combination of Tazocillin (70. 2 mg/24h) and Amikacin (7. 8 mg/24h), Suloerazon (41.6mg/24h) and Amikacin (7.8mg/24h) were 30,100,100,respectively. The infectious mice treated with Tienem (83.2 mg/24h)and Suloerazoa (83. 2 mg/24h) all died. Conclusion: There were obviously increased in MICs of common antibiotics for multi-drug resistant Acinetobacter baumarnii, but, the protective efficiency of Tazocillin on infectious mice is superior to the other antibiotics. It is more efficicently appling both Tazocillin and Amikacin, Suloerazon and Amikacin. But Tienem has antagonistic action on Amikacin or Tazocillin and so on. Reasonly, combinately, antibiotics application are available to multi-drug resistant Acinetobacter baumarnii, also reduce the
出处 《检验医学教育》 2006年第4期40-44,共5页
关键词 多重耐药 鲍曼不动杆菌 药物浓度 联合用药 药敏试验 Multidrug resistant Acinetobacter baumarnii Drug concentration Antibiotics combination Antibiotics Susceptibility test
  • 相关文献

参考文献6

二级参考文献45

  • 1王辉,刘颖梅,陈民钧,孙宏莉,谢秀丽,徐英春.鲍曼不动杆菌对碳青霉烯类耐药机制的研究[J].中国医学科学院学报,2003,25(5):567-572. 被引量:44
  • 2金正江,彭少华,李从荣.铜绿假单胞菌主动外排系统MexAB-OprM与耐药的关系研究[J].中华医院感染学杂志,2004,14(8):841-843. 被引量:30
  • 3周月清,陆开来,糜祖煌.鲍曼不动杆菌TEM基因及氨基糖苷类修饰酶基因初步研究[J].中华检验医学杂志,2005,28(2):200-202. 被引量:64
  • 4李仲兴 郑家齐.诊断细菌学[M].香港:黄河文化出版社,1992.295-297. 被引量:263
  • 5[3]Bou G, Oliver A, Martinez - Beltran J. OXA - 24. a novel class D betalactamase with carbapenemase activity in Acinetobacter baumannii clinical strain [J]. Antimicrob Agents Chemother, 2000, 44 ( 6 ): 1556 ~ 1561. 被引量:1
  • 6Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1990, 34(1): 52-57. 被引量:1
  • 7Yoshihara E,Nakae T.Identification of porins in the outer membrane of Pseudomonas aeruginosa that form small diffusion pores[J]. J Biol Chem, 1989, 264: 6297-6301. 被引量:1
  • 8Tsakris A, Pournaras S, Woodford N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece[J]. J Clin Microbiol, 2000, 38(3): 1290-1292. 被引量:1
  • 9Mutnick AH, Rhomberg PR, Sader HS, et al. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001)[J]. J Antimicrob Chemother, 2004, 53(2): 290-296. 被引量:1
  • 10National Committee for Clinical Laboratory Standard. Methods for dilution antimicrobiol susceptibility tests for bacterial that grow aerobically[S]. Approved standard M7-A4. 4th ed, Villanova, Pa: NCCLS, 2003. 被引量:1

共引文献340

同被引文献29

  • 1石岩,刘大为,许大波,徐英春,陈民均,王辉.泛耐药鲍曼不动杆菌感染临床治疗初探[J].中国感染与化疗杂志,2007,7(1):34-37. 被引量:112
  • 2Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infecions sensitive only to polymyxin B and sulbactam [ J ]. Lancet, 1994,344 ( 8933 ) : 1329-1332. 被引量:1
  • 3Higgins CS, Murtough SM, Williamson E, et al. Resistance to antibiotics and biocides among non-fermenting gram-negative bacteria [J]. Clin Microbiol Infect, 2001,7(6) :308-315. 被引量:1
  • 4Hsueh PR, Teng LJ, Chen CY, et al. Pandrug-resistant Acineto-bacter baumannii causing nosocomial infections in a university Hospital, Taiwan [ J ]. Emerg Infect Dis, 2002,8 ( 8 ) : 827-832. 被引量:1
  • 5Levin AS. Muhiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem [ J ]. Clin Microbiol Infect, 2002,8 ( 3 ) : 144-153. 被引量:1
  • 6Levin AS, Levy CE, Manrique AE, et al. Severe nosocomial infections with imipenem-resistant Acinetobaeter baumannii treated with ampieillin/sulbaetam[ J]. Int J Antimierob Agents, 2003,21 ( 1 ) : 58-62. 被引量:1
  • 7Marques MB, Brookings ES, Moser SA, et al. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations[J]. Antimicrob Agents Chemother, 1997,41 (5) :881-885. 被引量:1
  • 8Bauer G, Berens C, Projan S J, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe^2+ cleavage of 16S rRNA [ J ]. J Antimicrob Chemother, 2004,53 (4) :592-599. 被引量:1
  • 9Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines acomparative review with the tetracyclines [ J ]. Drugs, 2004,64 ( 1 ) :63-88. 被引量:1
  • 10Raeina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study[J]. Intensive Care Med, 2005,31 (8) :1058-1065. 被引量:1

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部